FOR PHYSICIANS
At Elios Therapeutics, our mission is to provide hope and access to individuals facing life-threatening diseases by offering innovative, personalized cancer immunotherapies.
Through the Right to Try program, we are committed to making our investigational TLPO vaccine available to patients who have exhausted standard treatment options and do not qualify for ongoing clinical trials.
How Patients Access the Progam
Patients interested in accessing a personalized TLPO vaccine under the federal Right to Try Act must follow a structured process to ensure eligibility, safety, and proper coordination with their medical team.
The steps include:
-
Contact Elios Therapeutics by email at Pauline.Nichol@eliosholdings.com to request access.
-
Receiving and reviewing the Right to Try Patient Packet, which includes:
-
Patient Instruction Letter
-
Informed Consent Form
-
Physician Request Letter Template
-
Cryoport Request Form
-
Authorization to Transfer Tissue Form
-
-
Engaging a licensed treating physician who will:
-
Submit a formal request to Elios
-
Oversee administration of the vaccine
-
Monitor and report any adverse events
-
Our Review and Decision Process
Once the request and required documents are received, our internal reviewer will evaluate the following:
-
Eligibility under the Right to Try Act
-
Availability of manufacturing capacity
-
Completeness of documentation
-
Feasibility of Cryoport scheduling and logistics
Elios Therapeutics does not reassess the patient's medical condition or question the treating physician's recommendation. We aim to approve eligible requests quickly and will notify the physician and patient of our decision within 4 business days.
Manufacturing and Delivery
-
Once approved, the patient will coordinate tumor tissue collection through their surgeon. Elios will provide a Cryoport system for secure sample delivery (minimum 5 business days' notice required).
-
Once the tissue is received and confirmed viable, the patient will receive an invoice for $25,000 to cover the patient's cost of vaccine manufacture.
-
After payment is received, Elios will produce the personalized TLPO vaccine within approximately five weeks and ship it directly to the physician for administration.
Commitment to Patients
We recognize the urgency that many patients face and are dedicated to making the Right to Try process transparent, respectful, and scientifically sound.
For questions or further assistance, patients and physicians can contact us at any time.
Contact Elios Therapeutics
Pauline Nichol, PA-C, Director of Clinical Operations
Email: Pauline.Nichol@eliosholdings.com
Website: www.eliostherapeutics.com